Editas Medicine (EDIT) Share-based Compensation (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Share-based Compensation data on file, last reported at $2.2 million in Q3 2025.

• Share-based Compensation for Q3 2025 came in at $2.2 million, down 53.6% year-over-year; the trailing twelve-month figure through Sep 2025 was $11.9 million (down 47.71% YoY), and the FY2024 annual result was $21.4 million, up 8.18% from the prior year.
• Share-based Compensation eased to $2.2 million in Q3 2025 per EDIT's latest filing, from $2.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $13.5 million in Q2 2021 and troughed at $2.2 million in Q3 2025.
• A 5-year average of $6.4 million and a median of $5.3 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2021 and 2025: Share-based Compensation surged 149.7% in 2021, then sank 60.73% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $7.7 million in 2021, then fell by 29.95% to $5.4 million in 2022, then dropped by 0.35% to $5.3 million in 2023, then slipped by 24.79% to $4.0 million in 2024, then plunged by 44.58% to $2.2 million in 2025.
• Business Quant data shows EDIT's Share-based Compensation at $2.2 million in Q3 2025, $2.7 million in Q2 2025, and $3.0 million in Q1 2025.